BRAF mutations and TERT promoter mutations have synergies in the diagnosis of thyroid cancer [37–42], and we have also found synergies between BRAF mutations and TERT promoter mutations in patients with melanomas [43–45], epithelial glioblastomas [46] and gliomas [47]. This evidence concerns the gene TERT and thyroid gland carcinoma.